wavebreakmedia / Shutterstock.com
The US National Institutes of Health (NIH) has decided not to exercise its “march in-rights” for the Xtandi (enzalutamide) prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
National Institutes of Health, Astellas Pharma, Xtandi, enzalutamide, Francis Collins, Bayh-Dole Act, patent, march-in rights, patent